Director, Clinical Research Division, Douglas Institute
After obtaining his medical degree at Université de Liège (Belgium) in 1972, Pierre Etienne moves to McGill University, where he does postgraduate work in neurochemistry in Theodore Sourkes’ laboratory.
From 1978 to 1983, Pierre Etienne directs a CIHR program grant on the biochemical, physiological and neuropathological basis of Alzheimer's disease that focuses on the cholinergic hypothesis. He later does brain imaging studies at the Montreal Neurological Institute and clinical studies with serotonergic agents at the Allan Memorial Institute.
In 1989, he joins Pfizer, and a year later, becomes Director of Experimental Medicine where he is responsible for the entire early development program (phase 1 and phase 2A) for all US- and Japan- discovered compounds, for exemple:
- Ziprasidone (Geodon)
- SP antagonist program
- CP 118991 (similar to Aricept)
In 2000 he is responsible for the full development and execution of all Pfizer clinical programs (phase 2B and phase 3) worldwide.
In 2003, he joins PhageTech, a biotechnology company committed to researching and developing new classes of synthetic antibiotics.The company becomes public in 2007 and is sold to The Medecines Company in 2009.
In December 2009, Pierre Etienne joins the Douglas Institute as a psychiatrist clinician. In 2011, he's appointed Director of the Clinical Research Division.
6875, boulevard LaSalle